Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03881488 · OUTCOME

Overall Survival

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies · Source last updated 2026-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From the first dose of CTX-471 to death

What was measured

Time from the first dose of CTX-471 to death

Groups in this outcome

CTX-471 Monotherapy 0.1 mg/kg

0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 0.3 mg/kg

0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 0.6 mg/kg

0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 1.2 mg/kg

1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Combination 0.1 mg/kg

0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

CTX-471 Combination 0.3 mg/kg

0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

CTX-471 Combination 0.6 mg/kg

0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CTX-471 Monotherapy 0.1 mg/kg3
CTX-471 Monotherapy 0.3 mg/kg33
CTX-471 Monotherapy 0.6 mg/kg36
CTX-471 Monotherapy 1.2 mg/kg7
CTX-471 Combination 0.1 mg/kg3
CTX-471 Combination 0.3 mg/kg9
CTX-471 Combination 0.6 mg/kg9

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
CTX-471 Monotherapy 0.1 mg/kg14.70Not reported9.5714.90Not reported
CTX-471 Monotherapy 0.3 mg/kg14.64Not reported1.3849.87Not reported
CTX-471 Monotherapy 0.6 mg/kg9.41Not reported0.7228.32Not reported
CTX-471 Monotherapy 1.2 mg/kg11.05Not reported2.4322.73Not reported
CTX-471 Combination 0.1 mg/kg4.05Not reported3.5526.78Not reported
CTX-471 Combination 0.3 mg/kg8.65Not reported0.2619.14Not reported
CTX-471 Combination 0.6 mg/kg6.78Not reported2.0721.48Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        9.57
        upper Limit
        14.90
        value
        14.70
      2. group Id
        OG001
        lower Limit
        1.38
        upper Limit
        49.87
        value
        14.64
      3. group Id
        OG002
        lower Limit
        0.72
        upper Limit
        28.32
        value
        9.41
      4. group Id
        OG003
        lower Limit
        2.43
        upper Limit
        22.73
        value
        11.05
      5. group Id
        OG004
        lower Limit
        3.55
        upper Limit
        26.78
        value
        4.05
      6. group Id
        OG005
        lower Limit
        0.26
        upper Limit
        19.14
        value
        8.65
      7. group Id
        OG006
        lower Limit
        2.07
        upper Limit
        21.48
        value
        6.78
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      33
    3. group Id
      OG002
      value
      36
    4. group Id
      OG003
      value
      7
    5. group Id
      OG004
      value
      3
    6. group Id
      OG005
      value
      9
    7. group Id
      OG006
      value
      9
    units
    Participants
description
Time from the first dose of CTX-471 to death
dispersion Type
Full Range
groups
  1. description
    0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG000
    title
    CTX-471 Monotherapy 0.1 mg/kg
  2. description
    0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG001
    title
    CTX-471 Monotherapy 0.3 mg/kg
  3. description
    0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG002
    title
    CTX-471 Monotherapy 0.6 mg/kg
  4. description
    1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG003
    title
    CTX-471 Monotherapy 1.2 mg/kg
  5. description
    0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG004
    title
    CTX-471 Combination 0.1 mg/kg
  6. description
    0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG005
    title
    CTX-471 Combination 0.3 mg/kg
  7. description
    0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG006
    title
    CTX-471 Combination 0.6 mg/kg
param Type
MEDIAN
reporting Status
POSTED
time Frame
From the first dose of CTX-471 to death
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice